QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two posters on its PI3K inhibitor compound, AEZS-126, as well as a poster on its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on April 18-22, 2009 at the Colorado Convention Center in Denver, Colorado.
AEZS-126 (Poster #3705) - Entitled, "AEZS-126, a new orally bioavailable PI3K inhibitor with antitumor effects", I. Seipelt, S. Baasner, M. Gerlach, M. Teifel, J. Fensterle, L. Blumenstein, G. Mueller and E. Guenther, the poster focuses on ADMET and safety profiling of the compound, as well as in vivo pharmacokinetic experiments and mouse xenograft antitumor studies. AEZS-126 (Poster #3706) - Entitled, "In vitro profiling of the potent and selective PI3K inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G. Mueller, M.Teifel, E. Polymeropoulos and E. Guenther, the poster outlines the key in vitro characteristics of this compound that led to its selection for in vivo development. Both posters will be presented on Tuesday, April 21, 2009, between 8 a.m. and 12 p.m. (MT), during the Experimental and Molecular Therapeutics 23 session in Hall B-F, Poster Section 35. AEZS-112 (Poster #5567) - Entitled, "Phase I dose-escalation, safety, and pharmacokinetic study of weekly oral AEZS-112, a small molecule anticancer agent in patients with advanced cancer and lymphoma", D. W. Northfelt, P. Griffin, H. Block, H. Sindermann, M. Teifel, D. Von Hoff, D. Mendelson, the poster outlines Phase 1 result
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2009 PR Newswire.
All rights reserved